Muscle Preservation in Obesity Therapy: How Drug Developers Can Take Advantage of MyoScreen™ to Distinguish Direct From Systemically-Mediated Drug Effects on Human Muscle

• Investigation of GLP-1 agonist effects in human myotubes
• Benchmarking an ALK5 inhibitor against bimagrumab across muscle-related assays
• Towards a broader investigation of muscle functions in situations of wasting

Speakers:

Mélanie Flaender

Head of Project Management

Cytoo